Cargando…
Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served as an important part of the treatment armamentarium for prostate cancer. The introduction of LA depot formulations provided a significant improvement in the acceptance of this...
Autores principales: | Tunn, Ulf W, Gruca, Damian, Bacher, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639016/ https://www.ncbi.nlm.nih.gov/pubmed/23637525 http://dx.doi.org/10.2147/CIA.S27931 |
Ejemplares similares
-
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009) -
A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
por: Tunn, Ulf W
Publicado: (2011) -
Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study
por: Braeckman, Johan, et al.
Publicado: (2014) -
Leuprorelin depot injection: patient considerations in the management of prostatic cancer
por: Abouelfadel, Zinelabidine, et al.
Publicado: (2008) -
Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate
por: Okada, Akie, et al.
Publicado: (2022)